CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (USD $) In Thousands, except Share data, unless otherwise specified	Total	Valeant Pharmaceuticals International, Inc. Shareholders' equity	Common Shares	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive (Loss) Income	Noncontrolling Interest	Comprehensive Loss
Balance at Dec. 31, 2009	$ 1,354,372	$ 1,354,372	$ 1,465,004	$ 91,768	$ (245,974)	$ 43,574
Balance (in shares) at Dec. 31, 2009			158,311,000
Increase (Decrease) in Shareholders' Equity
Acquisition of Valeant, equity issued	3,880,301	3,880,301	3,710,888	169,413
Acquisition of Valeant, equity issued (in shares)			139,267,000
Fair value of equity component of Valeant 4.0% Convertible Notes and call options	253,971	253,971		253,971
Repurchase of equity component of 5.375% Convertible Notes	(131,723)	(131,723)		(20,444)	(111,279)
Common shares issued under share-based compensation plans	58,425	58,425	110,513	(52,088)
Common shares issued under share-based compensation plans (in shares)			6,959,000
Equity settlement and reclassification of call options	(32,694)	(32,694)	3,602	(38,224)	1,928
Equity settlement and reclassification of call options (in shares)			145,000
Repurchase of common shares	(60,130)	(60,130)	(40,442)		(19,688)
Repurchase of common shares (in shares)			(2,305,000)
Share-based compensation	98,033	98,033		98,033
Employee withholding taxes related to share-based awards	(14,485)	(14,485)		(14,485)
Cash dividends declared and dividend equivalents ($1.28 per share)	(342,043)	(342,043)		7,097	(349,140)
Cash dividends reinvested through dividend reinvestment plan			2,165		(2,165)
Cash dividends reinvested through dividend reinvestment plan (in shares)			72,000
Total before comprehensive income (loss)	5,064,027	5,064,027	5,251,730	495,041	(726,318)	43,574
Total before comprehensive income (loss) (in shares)			302,449,000
Comprehensive loss:
Net (loss) income	(208,193)	(208,193)			(208,193)			(208,193)
Other comprehensive income (loss)	55,262	55,262				55,262		55,262
Total comprehensive loss	(152,931)	(152,931)						(152,931)
Balance at Dec. 31, 2010	4,911,096	4,911,096	5,251,730	495,041	(934,511)	98,836
Balance (in shares) at Dec. 31, 2010			302,449,000
Increase (Decrease) in Shareholders' Equity
Settlement of 4% Convertible Notes for the year 2011 and 5.375% Convertible Notes for the year 2012, respectively	225,983	225,983	892,000	(225,971)	(440,046)
Settlement of 4% Convertible Notes for the year 2011 and 5.375% Convertible Notes for the year 2012, respectively (in shares)			17,783,000
Repurchase of equity component of 5.375% Convertible Notes	(414,003)	(414,003)		(33,169)	(380,834)
Common shares issued under share-based compensation plans	41,717	41,717	121,099	(79,382)
Common shares issued under share-based compensation plans (in shares)			4,338,000
Equity settlement and reclassification of call options	(66,863)	(66,863)	(36,343)	11,072	(41,592)
Equity settlement and reclassification of call options (in shares)			(2,999,000)
Repurchase of common shares	(639,242)	(639,242)	(264,865)		(374,377)
Repurchase of common shares (in shares)			(15,200,000)
Share-based compensation	94,023	94,023		94,023
Employee withholding taxes related to share-based awards	(37,702)	(37,702)		(19,211)	(18,491)
Tax benefits from stock options exercised	26,414	26,414		26,414
Reclassification of deferred share units	9,271	9,271		9,271
Noncontrolling interest from business combinations	58,555						58,555
Acquisition of noncontrolling interest	(58,320)	(1,971)		(1,971)			(56,349)
Total before comprehensive income (loss)	4,150,929	4,148,723	5,963,621	276,117	(2,189,851)	98,836	2,206
Total before comprehensive income (loss) (in shares)			306,371,000
Comprehensive loss:
Net (loss) income	159,559	159,559			159,559			159,559
Other comprehensive income (loss)	(380,658)	(378,452)				(378,452)	(2,206)	(380,658)
Total comprehensive loss	(221,099)	(218,893)					(2,206)	(221,099)
Balance at Dec. 31, 2011	3,929,830	3,929,830	5,963,621	276,117	(2,030,292)	(279,616)
Balance (in shares) at Dec. 31, 2011	306,371,032		306,371,000
Increase (Decrease) in Shareholders' Equity
Settlement of 4% Convertible Notes for the year 2011 and 5.375% Convertible Notes for the year 2012, respectively	(43,768)	(43,768)		(175)	(43,593)
Repurchase of equity component of 5.375% Convertible Notes	(2,862)	(2,862)		(180)	(2,682)
Common shares issued under share-based compensation plans	23,023	23,023	79,371	(56,348)
Common shares issued under share-based compensation plans (in shares)			2,747,000
Repurchase of common shares	(280,724)	(280,724)	(102,340)		(178,384)
Repurchase of common shares (in shares)			(5,257,000)
Share-based compensation	66,236	66,236		66,236
Employee withholding taxes related to share-based awards	(31,073)	(31,073)		(31,073)
Tax benefits from stock options exercised	12,541	12,541		12,541
Total before comprehensive income (loss)	3,673,203	3,673,203	5,940,652	267,118	(2,254,951)	(279,616)
Total before comprehensive income (loss) (in shares)			303,861,000
Comprehensive loss:
Net (loss) income	(116,025)	(116,025)			(116,025)			(116,025)
Other comprehensive income (loss)	160,220	160,220				160,220		160,220
Total comprehensive loss	44,195	44,195						44,195
Balance at Dec. 31, 2012	$ 3,717,398	$ 3,717,398	$ 5,940,652	$ 267,118	$ (2,370,976)	$ (119,396)
Balance (in shares) at Dec. 31, 2012	303,861,272		303,861,000